NYSE:MDT

Medtronic Inc (MDT)

80.83
-0.15 (0.19%)
as of Jun 29, 2026, 7:17:55 pm Market Open.
182 watching
0
Investor Insights
star iconJun 29, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Experts have mixed opinions on Medtronic Inc (MDT-N), with one reviewing it positively, stating that the company is set to capitalize on advancements in AI, alongside the strong market demographics of the Baby Boomer population. The other expert, however, is more skeptical, acknowledging that while MDT is making gains against competitors like Boston Scientific, it lacks the substantial R&D capabilities necessary for sustained leadership in the long run. There is caution expressed that the investment may not be suitable for those looking for a long-term hold, as the focus is more on trading amidst anticipated product launches that could support the stock's upward movement for up to 18 months. Ultimately, while MDT may have a diversified product range which provides some advantage, the lack of a strong R&D pipeline compared to its peers raises concerns about its future competitiveness.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
Stryker, SYK
TOP PICK
He has a model price of $41.29 giving it a 21% positive differential. Just reported greater earnings. 2% yield.
BUY
Likes medical devices sector. Of all the sectors, medical equipment is one of the tops. Regardless of what is going on in the economies , medical devices will continue to sell. He owns Zoll Medical (ZOLL-Q) instead, which has more growth potential. Thinks there is more upside potential in the small/mid-cap size names.
BUY
PE of about 20 and anticipated growth rate of about 14%. Have a lot of intellectual property. Reasonably attractive.
DON'T BUY
His model price is $41.45 so it is a negative 23%-24% differential. This is one of those stocks that is perpetually overvalued.
BUY
Likes a lot of the big US healthcare stocks. Valuation is reasonable.
BUY ON WEAKNESS
On his watch list as a possible investment. Valuation has been hurt but the fundamentals have not changed much. The long-term outlook for their products is very good.
TOP PICK
A high quality, growth company. Good price. The leading medical technology company in the world.
TOP PICK
Solid earnings. Feels their new stent will be successful next year.
DON'T BUY
Interesting company. Market is very strong for their products. Stock isn't cheap. Has been growing slowely
DON'T BUY
Valuation is a little bit ahead of the stock. Very good management.
DON'T BUY
Competition. Too expensive at 30 X earnings.
BUY ON WEAKNESS
Great company. Buy in the mid to low $20's.
TOP PICK
Good company. Not a cheap stock. A cash machine.
BUY
Good price now. Good mngmnt.
PAST TOP PICK
Good acquisition. Fairly expensive, but the dominant player. No debt. Good dividends.
Showing 106 to 120 of 125 entries